Kymera Therapeutics reports Q2 2025 results, plans call on August 11.
ByAinvest
Monday, Aug 4, 2025 7:02 am ET1min read
KYMR--
Kymera Therapeutics is a biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological diseases. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years [2].
Investors and financial professionals are encouraged to register for the video call or view the livestreamed webcast via the provided link. A replay of the webcast will be archived and available following the event. For more information about Kymera’s science, pipeline, and people, please visit the company’s website or follow them on X or LinkedIn.
References:
[1] https://www.stocktitan.net/news/KYMR/kymera-therapeutics-to-report-second-quarter-2025-financial-results-za29t21v5aby.html
[2] https://www.kymeratx.com
• Kymera Therapeutics reports Q2 2025 financial results on August 11, 2025 • 8:30 a.m. ET video conference call and webcast to follow • Registration link: www.kymeratx.com/investors • Replay of webcast available after the event • Kymera is a clinical-stage biotech company pioneering targeted protein degradation • Developing medicines for critical health problems and improving patients' lives • Focusing on disease targets and pathways inaccessible with conventional therapies.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 11, 2025. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website [1].Kymera Therapeutics is a biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological diseases. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years [2].
Investors and financial professionals are encouraged to register for the video call or view the livestreamed webcast via the provided link. A replay of the webcast will be archived and available following the event. For more information about Kymera’s science, pipeline, and people, please visit the company’s website or follow them on X or LinkedIn.
References:
[1] https://www.stocktitan.net/news/KYMR/kymera-therapeutics-to-report-second-quarter-2025-financial-results-za29t21v5aby.html
[2] https://www.kymeratx.com
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet